Interview with Jean-Luc Bélingard, CEO, Ipsen France
As the G5 brings together five very different companies – Ipsen, LFB, Pierre Fabre, Sanofi-Aventis, Servier – could you explain the origin behind the creation and the purpose of the…
Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology. Ipsen’s commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer or neuroendocrine tumors. Ipsen also has a significant presence in primary care. Moreover, the Group has an active policy of partnerships. Ipsen’s R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis, France; Slough/Oxford, UK; Cambridge, US).
2015 has been Ipsen´s best year since becoming a publicly traded company, marked by their take-off in the US. In 2016 the US will overtake France to become their number one affiliate. Besides an excellent 2015 operating performance, sales grew by more than 10% year-on-year, driven by the successful launch of Somatuline in neuroendocrine tumors in the US and Europe, and the performance of Dysport in aesthetics. Core operating income grew by close to 24%, reflecting continuous transformation and cost monitoring efforts.
Contact
Address: 65 Quai Georges Gorse 92100, Boulogne-Billancourt,France
Tel: +33 (0)1 58 33 50 00
Web: http://www.ipsen.com/en/ipsen-worldwide
As the G5 brings together five very different companies – Ipsen, LFB, Pierre Fabre, Sanofi-Aventis, Servier – could you explain the origin behind the creation and the purpose of the…
France is attempting to reposition itself as a globally competitive hub for artificial intelligence R&D, with significant state investment aiming to turn Paris into the next Palo Alto. With rapid…
Professor José-Alain Sahel, founder and director of the Institute de la Vision in Paris, offers his insider take on the ophthalmology landscape in France, international perceptions of the country, and…
Bertrand Letartre of Anios discusses the company’s rich history, their move towards more technical offerings with the acquisition of Soluscope, internationalization, family values, and the company’s mission to spread awareness…
In an exclusive interview, Agnès Buzyn, Chairwoman of the Board for the French National Authority for Health (Haute Autorité de Santé – HAS), on her organization’s priorities, the particularities of…
Shedding light on the unique business model of French pharma’s most successful mid-cap. Not long ago, Laboratories Servier was considered a somewhat mysterious and opaque actor on the world…
Due to high unmet medical need, oncology is set to remain as the number one therapeutic area globally in the coming years. France has traditionally been a leader in this…
AFKLM Cargo’s Director Pharma, Renate de Walle and Sales & Business Developer Manager Pharma France, Fabrice Panza speak about AFKLM Cargo recently achieved IATA Centre of Excellence for Independent Validators…
Lyon’s innovative roots, favourable location, educational excellence, and collaborative culture are all helping to make the city a premium life science, pharmaceuticals and biotech hub, not just in France, but globally. The…
Philippe Choukroun (PC) and Patricia Hatesuer (PH) of AAA speak about the Alsace region in France and the attractiveness of the life science cluster within the tri-national Biovalley area. They…
France provides a unique environment for dermo-cosmetics companies such as Pierre Fabre, Uriage, and Galderma to thrive in terms of the industry’s historical legacy in the country, abundant natural resources, and a…
France has a rich history in innovation, especially in the medical devices sector, but has not been able to produce a giant in the sector to compare with the global impact of…
Orange Healthcare CEO Elie Lobel discusses the importance of digitalization to the healthcare industry, major challenges, and the tremendous work that has already been done in the e-health regulatory field…
See our Cookie Privacy Policy Here
